# US 2026/0092076 A1 · Novel compounds

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0092076 A1
- Document ID: US20260092076A1
- Status: Published application
- Kind: A1
- Application number: 19/351,608
- Filed: 2025-10-07
- Published: 2026-04-02
- Earliest claimed: 2023-04-12
- Assignees: Hoffmann-La Roche Inc.
- Applicants: Hoffmann-La Roche Inc.
- Inventors: Lewis Scott AITKEN; Lea Aurelie BOUCHE; Wolfgang GUBA; Georg Stefan JAESCHKE; Stefanie Katharina MESCH; Christian SCHNIDER; Jonathan Martin SHANNON; Sandra STEINER
- Web page: https://patentgrep.com/patent/US20260092076A1

## CPC

- C07D 519/00: Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
- A61K 31/437: the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A61K 31/4375: the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
- A61K 31/4725: containing further heterocyclic rings
- A61K 31/4985: Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
- A61K 31/5025: ortho- or peri-condensed with heterocyclic ring systems
- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 37/02: Immunomodulators
- C07D 498/04: Ortho-condensed systems
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention relates to novel compounds having the general formula I wherein R1, R2, R3, A and W are as described herein, composition including the compounds and methods of using the compounds.

## Claims

### Claim 1

A compound of formula I:
wherein,
R1 is H, alkyl, hydroxyalkyl or alkoxyalkyl;
R2 is halo, haloalkyl or cyano;
R3 is H;
or R2 and R3, and the atoms to which they are bonded, form a 4-6 membered heterocycle ring comprising a single O heteroatom optionally substituted with one or two substituents independently selected from halo and alkyl,
or R2 and R3, and the atoms to which they are bonded, form a 3-6 membered cycloalkyl ring optionally substituted with one or two substituents independently selected from halo and alkyl;
A is CH or N;
W is:
p is 1 or 2;
q is 1 or 2;
m is 0 or 1;
Y1 is C═O, CH, CH2, C—Rx, N, or NH;
Y2 is C═O, CH, C—Ry, O, N, NH, or N—CH3;
Y3 is C═O, CH, CH2, CRy, N, NH, or NRz;
Y4 is C═O, CH, CRy, N, NH or N—CH3;
wherein Rx is H and each Ry is independently selected from —OH, alkyl, alkoxy, cyano and halo, or Rx+Ry, through the atoms to which they are attached, form a heterocycle ring;
Rz is H, alkyl or hydroxyalkyl;
and pharmaceutically acceptable salts thereof.

### Claim 2 (depends on 1)

A compound according to claim 1, wherein R1 is alkyl or hydroxyalkyl.

### Claim 3 (depends on 1)

A compound according to claim 1, wherein R1 is alkyl.

### Claim 4 (depends on 1)

A compound according to claim 1, wherein n is 1, q is 1, and m is 1.

### Claim at position 5

5-6. (canceled)

### Claim 7 (depends on 1)

A compound according to claim 1, wherein Y1 is CH, C—Rx, N, or NH.

### Claim 8 (depends on 1)

A compound according to claim 1, wherein Y1 is CH, N, or NH.

### Claim 9

(canceled)

### Claim 10 (depends on 1)

A compound according to claim 1, wherein Y2 is C═O, CH, C—Ry, N, or NH.

### Claim 11

(canceled)

### Claim 12 (depends on 1)

A compound according to claim 1, wherein Y3 is C═O, CH, C—Ry, N, NH, or NRz.

### Claim at position 12

13-14. (canceled)

### Claim 15 (depends on 1)

A compound according to claim 1, wherein each Ry is independently selected from OH, alkyl, alkoxy, cyano, and halo.

### Claim 16

(canceled)

### Claim 17 (depends on 1)

A compound according to claim 1, wherein each Rz is H, alkyl, or hydroxyalkyl.

### Claim 18

(canceled)

### Claim 19 (depends on 1)

A compound according to claim 1, wherein,
R1 is alkyl or hydroxyalkyl;
R2 is halo, haloalkyl, or cyano;
R3 is H;
A is CH or N;
p is 1 or 2;
q is 1 or 2;
m is 0 or 1;
Y1 is CH, C—Rx, N, or NH;
Y2 is C═O, CH, C—Ry, N, or NH;
Y3 is C═O, CH, CRy, N, NH, or NRz;
Y4 is C═O, CH, CRy, N, NH, or N—CH3;
wherein Rx is H and each Ry is independently selected from OH, alkyl, alkoxy, cyano and halo, or Rx+Ry, through the atoms to which they are attached, form a heterocycle ring comprising 1 or 2 oxygen heteroatoms;
Rz is H, alkyl, or hydroxyalkyl;
and pharmaceutically acceptable salts thereof.

### Claim 20 (depends on 1)

A compound according to claim 1, wherein,
R1 is alkyl;
R2 is halo, haloalkyl, or cyano;
R3 is H;
A is CH or N;
p is 1 or 2;
q is 1;
m is 0 or 1;
Y1 is CH, N, or NH;
Y2 is C═O, CH, C—Ry, N, or NH;
Y3 is CH, N, NH, or NRz;
Y4 is CH or N;
wherein each Ry is alkyl;
Rz is H, alkyl, or hydroxyalkyl;
and pharmaceutically acceptable salts thereof.

### Claim 21 (depends on 1)

A compound according to claim 1, wherein,
R1 is alkyl;
R2 is halo, haloalkyl, or cyano;
R3 is H;
A is CH or N;
p is 1 or 2;
q is 1;
m is 0 or 1;
Y1 is CH, N, or NH;
Y2 is C═O, CH, C—Ry, N, or NH;
Y3 is CH, N, NH or NRz; and
Y4 is CH or N;
wherein each Ry is alkyl; and Rz is hydroxyalkyl,
and pharmaceutically acceptable salts thereof.

### Claim 22 (depends on 1)

A compound according to claim 1, wherein,
R1 is alkyl;
R2 is halo, haloalkyl, or cyano;
R3 is H;
A is CH or N;
p is 1;
q is 1;
m is 1;
Y1 is CH;
Y2 is C═O or N;
Y3 is CH, NH or NRz;
Y4 is CH;
Rz is hydroxyalkyl;
and pharmaceutically acceptable salts thereof.

### Claim 23 (depends on 1)

A compound according to claim 1, selected from:
2-[5-[2-Hydroxy-6-methyl-4-(trifluoromethyl)phenyl]oxazolo[4,5-b]pyridin-2-yl]-3,5-dihydro-1H-pyrrolo[3,4-c]pyridin-6-one;
2-[5-[2-Hydroxy-6-methyl-4-(trifluoromethyl)phenyl]oxazolo[4,5-b]pyridin-2-yl]-5-methyl-1,3-dihydropyrrolo[3,4-c]pyridin-6-one;
3-Hydroxy-5-methyl-4-[2-(6-oxo-3,5-dihydro-1H-pyrrolo[3,4-c]pyridin-2-yl)oxazolo[4,5-b]pyridin-5-yl]benzonitrile;
2-[5-(4-Chloro-2-hydroxy-6-methyl-phenyl)oxazolo[4,5-b]pyridin-2-yl]-3,5-dihydro-1H-pyrrolo[3,4-c]pyridin-6-one;
5-(2-Hydroxyethyl)-2-[5-[2-hydroxy-6-methyl-4-(trifluoromethyl)phenyl]oxazolo[4,5-b]pyridin-2-yl]-1,3-dihydropyrrolo[3,4-c]pyridin-6-one;
5-Chloro-2-(2-isoindolin-2-yloxazolo[4,5-b]pyridin-5-yl)-3-methyl-phenol;
5-chloro-2-[2-(1,3-dihydropyrrolo[3,4-c]pyridin-2-yl)oxazolo[4,5-b]pyridin-5-yl]-3-methyl-phenol;
2-[5-(4-Chloro-2-hydroxy-6-methyl-phenyl)oxazolo[4,5-b]pyridin-2-yl]isoindolin-5-ol;
5-Chloro-2-[2-(4-fluoroisoindolin-2-yl)oxazolo[4,5-b]pyridin-5-yl]-3-methyl-phenol;
4-[2-(1,3-dihydropyrrolo[3,4-c]pyridin-2-yl)oxazolo[4,5-b]pyridin-5-yl]-3-hydroxy-5-methyl-benzonitrile;
5-chloro-3-methyl-2-[2-(2-methyl-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-6-yl)oxazolo[4,5-b]pyridin-5-yl]phenol;
2-[2-(6-methoxy-1,3-dihydropyrrolo[3,4-c]pyridin-2-yl)oxazolo[4,5-b]pyridin-5-yl]-3-methyl-5-(trifluoromethyl)phenol;
5-chloro-2-[2-(5,7-dihydropyrrolo[3,4-d]pyrimidin-6-yl)oxazolo[4,5-b]pyridin-5-yl]-3-methyl-phenol; formic acid;
5-chloro-2-[2-(5,7-dihydropyrrolo[3,4-d]pyrimidin-6-yl)oxazolo[4,5-b]pyridin-5-yl]-3-methyl-phenol;
5-chloro-2-[2-(4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-5-yl)oxazolo[4,5-b]pyridin-5-yl]-3-methyl-phenol;
5-chloro-2-[2-(3,4-dihydro-1H-2,7-naphthyridin-2-yl)oxazolo[4,5-b]pyridin-5-yl]-3-methyl-phenol;
3-hydroxy-4-(2-isoindolin-2-yloxazolo[4,5-b]pyridin-5-yl)-5-methyl-benzonitrile;
4-[2-(7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-6-yl)oxazolo[4,5-b]pyridin-5-yl]-3-hydroxy-5-methyl-benzonitrile;
2-[2-(5,7-dihydropyrrolo[3,4-d]pyrimidin-6-yl)oxazolo[4,5-b]pyridin-5-yl]-3-methyl-5-(trifluoromethyl)phenol;
7-[5-[2-hydroxy-6-methyl-4-(trifluoromethyl)phenyl]oxazolo[4,5-b]pyridin-2-yl]-2,5,6,8-tetrahydro-2,7-naphthyridin-3-one;
6-[5-[2-hydroxy-6-methyl-4-(trifluoromethyl)phenyl]oxazolo[4,5-b]pyridin-2-yl]-5,7-dihydro-1H-pyrrolo[3,4-b]pyridin-2-one;
6-[5-[2-hydroxy-6-methyl-4-(trifluoromethyl)phenyl]oxazolo[4,5-b]pyridin-2-yl]-1-methyl-5,7-dihydropyrrolo[3,4-b]pyridin-2-one;
6-[5-[2-hydroxy-6-methyl-4-(trifluoromethyl)phenyl]oxazolo[4,5-b]pyridin-2-yl]-2-methyl-5,7-dihydropyrrolo[3,4-c]pyridazin-3-one;
2-[2-(5,7-dihydropyrrolo[3,4-b]pyrazin-6-yl)oxazolo[4,5-b]pyridin-5-yl]-3-methyl-5-(trifluoromethyl)phenol;
2-[2-(7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-6-yl)oxazolo[4,5-b]pyridin-5-yl]-3-methyl-5-(trifluoromethyl)phenol;
5-chloro-3-methyl-2-[2-(2,4,6,7-tetrahydropyrazolo[4,3-c]pyridin-5-yl)oxazolo[4,5-b]pyridin-5-yl]phenol;
5-(difluoromethyl)-2-[2-(7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-6-yl)oxazolo[4,5-b]pyridin-5-yl]-3-methyl-phenol;
7-[5-(4-chloro-2-hydroxy-6-methyl-phenyl)oxazolo[4,5-b]pyridin-2-yl]-2,5,6,8-tetrahydro-2,7-naphthyridin-3-one;
5-Chloro-2-[2-(1,3-dihydropyrrolo[3,4-c]pyridin-2-yl)oxazolo[4,5-b]pyrazin-5-yl]-3-methyl-phenol; formic acid;
5-Chloro-2-[2-(1,3-dihydropyrrolo[3,4-c]pyridin-2-yl)oxazolo[4,5-b]pyrazin-5-yl]-3-methyl-phenol;
5-Chloro-2-[2-(1,3-dihydropyrrolo[3,4-c]pyridin-2-yl)oxazolo[4,5-b]pyrazin-5-yl]-3-(hydroxymethyl)phenol;
5-Chloro-2-[2-(7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-6-yl)oxazolo[4,5-b]pyridin-5-yl]-3-methyl-phenol;
5-Chloro-2-[2-(2-methoxy-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-6-yl)oxazolo[4,5-b]pyridin-5-yl]-3-methyl-phenol;
2-[5-(4-Chloro-2-hydroxy-6-methyl-phenyl)oxazolo[4,5-b]pyridin-2-yl]-3,4-dihydro-1H-isoquinoline-5-carbonitrile;
5-Chloro-2-[2-(5-methoxy-3,4-dihydro-1H-isoquinolin-2-yl)oxazolo[4,5-b]pyridin-5-yl]-3-methyl-phenol;
5-Chloro-2-[2-(7-fluoro-3,4-dihydro-1H-isoquinolin-2-yl)oxazolo[4,5-b]pyridin-5-yl]-3-methyl-phenol;
6-[5-(4-Chloro-2-hydroxy-6-methyl-phenyl)oxazolo[4,5-b]pyridin-2-yl]-1,5,7,8-tetrahydropyrido[4,3-d]pyrimidin-2-one;
6-[5-(4-Chloro-2-hydroxy-6-methyl-phenyl)oxazolo[4,5-b]pyridin-2-yl]-1,5,7,8-tetrahydro-1,6-naphthyridin-2-one;
6-[5-(4-Chloro-2-hydroxy-6-methyl-phenyl)oxazolo[4,5-b]pyridin-2-yl]-5,7-dihydro-2H-pyrrolo[3,4-c]pyridazin-3-one;
5-chloro-2-[2-(7,8-dihydro-5H-pyrido[3,4-b]pyrazin-6-yl)oxazolo[4,5-b]pyridin-5-yl]-3-methyl-phenol;
6-[5-[2-hydroxy-6-methyl-4-(trifluoromethyl)phenyl]oxazolo[4,5-b]pyridin-2-yl]-3,5,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-one;
5-chloro-2-(2-(6,8-dihydro-7H-[1,3]dioxolo[4,5-e]isoindol-7-yl)oxazolo[4,5-b]pyridin-5-yl)-3-methylphenol; and
pharmaceutically acceptable salts thereof.

### Claim at position 22

24-27. (canceled)

### Claim 28 (depends on 1)

A method of treating a disease, disorder or condition responsive to NLRP3 inhibition in a subject in need thereof, comprising administering a therapeutically effective amount of a compound according to claim 1.

### Claim 29 (depends on 1)

A pharmaceutical composition comprising a compound according to claim 1 and a therapeutically inert carrier.

### Claim 30

(canceled)

### Claim 31 (depends on 28)

The method of claim 28, wherein the disease, disorder or condition is selected from Asthma and chronic obstructive pulmonary disorder (COPD).

### Claim 32 (depends on 28)

The method of claim 28, wherein the disease, disorder or condition is selected from Parkinson's Disease and Alzheimer's Disease.

### Claim at position 28

33-34. (canceled)

### Claim 35 (depends on 1)

A method of inhibiting NLRP3 in a subject in need thereof, which method comprises administering to the subject an effective amount of a compound of claim 1.

### Claim at position 30

36-38. (canceled)
